Published in Eur J Heart Fail on July 07, 2006
Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA (2013) 4.17
Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation (2007) 2.14
Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol (2007) 1.92
Prospective analysis of LDL-C goal achievement and self-reported medication adherence among statin users in primary care. Clin Ther (2011) 1.58
Aspirin use in heart failure: is low-dose therapy associated with mortality and morbidity benefits in a large community population? Circ Heart Fail (2014) 1.40
MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure. Eur J Heart Fail (2015) 1.24
Heart failure management programs: can we afford to ignore the inpatient phase of care? J Card Fail (2003) 1.12
Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover. Eur J Heart Fail (2009) 1.12
Trafficking of immature DeltaF508-CFTR to the plasma membrane and its detection by biotinylation. Biochem J (2009) 1.04
Is multidisciplinary care of heart failure cost-beneficial when combined with optimal medical care? Eur J Heart Fail (2003) 1.04
The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients. J Card Fail (2007) 1.02
Outpatient intravenous diuretic therapy; potential for marked reduction in hospitalisations for acute decompensated heart failure. Eur J Heart Fail (2008) 0.96
Clinical deterioration in established heart failure: what is the value of BNP and weight gain in aiding diagnosis? Eur J Heart Fail (2005) 0.96
Quality of life predicts outcome in a heart failure disease management program. Int J Cardiol (2008) 0.94
Decompensation of chronic heart failure associated with pregabalin in patients with neuropathic pain. J Card Fail (2007) 0.94
Multiple neurohumoral modulating agents in systolic dysfunction heart failure: are we lowering blood pressure too much? J Card Fail (2008) 0.93
Heart failure management: multidisciplinary care has intrinsic benefit above the optimization of medical care. J Card Fail (2002) 0.90
Nitric oxide-matrix metaloproteinase-9 interactions: biological and pharmacological significance--NO and MMP-9 interactions. Biochim Biophys Acta (2014) 0.89
Doppler-echocardiographic indices of diastolic function in heart failure admissions with preserved left ventricular systolic function. Eur J Heart Fail (2002) 0.87
Attenuation of monocyte chemotaxis--a novel anti-inflammatory mechanism of action for the cardio-protective hormone B-type natriuretic peptide. J Cardiovasc Transl Res (2013) 0.83
Progression of preserved systolic function heart failure to systolic dysfunction -- a natural history study. Int J Cardiol (2006) 0.83
Are beta2-agonists responsible for increased mortality in heart failure? Eur J Heart Fail (2011) 0.79
Modest elevation in BNP in asymptomatic hypertensive patients reflects sub-clinical cardiac remodeling, inflammation and extracellular matrix changes. PLoS One (2012) 0.79
Fluid restriction in the management of decompensated heart failure: no impact on time to clinical stability. J Card Fail (2007) 0.79
Very late bare-metal stent thrombosis, rare but stormy! J Invasive Cardiol (2011) 0.78
Imaging and organelle distribution of fluorescent InGaP/ZnS nanoparticles in glial cells. Nanomedicine (Lond) (2009) 0.77
Causes and consequences of nonpersistence with heart failure medication. Am J Cardiol (2009) 0.77
Integration of B-type natriuretic Peptide in heart failure outpatient programs. Congest Heart Fail (2008) 0.77
Specialist nurse supervised in-hospital titration to target dose ACE inhibitor--is it safe and feasible in a community heart failure population? Eur J Cardiovasc Nurs (2003) 0.77
Long-term statin therapy in patients with systolic heart failure and normal cholesterol: effects on elevated serum markers of collagen turnover, inflammation, and B-type natriuretic peptide. Clin Ther (2011) 0.77
Heart failure care in a hospital unit: a comparison of standard 3-month and extended 6-month programs. Eur J Heart Fail (2005) 0.76
Improvement but no cure of left ventricular systolic dysfunction in treated heart failure patients. Eur J Heart Fail (2007) 0.76
Differential inhibition of tumour cell-induced platelet aggregation by the nicotinate aspirin prodrug (ST0702) and aspirin. Br J Pharmacol (2012) 0.76
Mechanisms of aggregation inhibition by aspirin and nitrate-aspirin prodrugs in human platelets. J Pharm Pharmacol (2011) 0.76
Extracellular matrix sub-types and mechanical stretch impact human cardiac fibroblast responses to transforming growth factor beta. Connect Tissue Res (2014) 0.76
Prevalence of heart failure: a reflection of the good and the bad of modern cardiovascular care. Rev Esp Cardiol (2008) 0.75
The St Vincent's potentially inappropriate medicines study: development of a disease-specific consensus list and its evaluation in ambulatory heart failure care. Eur J Heart Fail (2014) 0.75
Need and evolution of need for device therapy in a community heart failure population. Eur J Heart Fail (2008) 0.75
B-type natriuretic peptide measurement in primary care; magnitude of associations with cardiovascular risk factors and their therapies. Observations from the STOP-HF (St. Vincent's Screening TO Prevent Heart Failure) study. Clin Chem Lab Med (2011) 0.75
Multidisciplinary care of heart failure: what have we learned and where can we improve? Eur J Cardiovasc Nurs (2003) 0.75
Role of Monitoring Devices in Preventing Heart Failure Admissions. Curr Heart Fail Rep (2015) 0.75